Adverum Biotechnologies, Inc. (ADVM)
| Market Cap | 1.31B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -98.80M |
| Shares Out | 88.87M |
| EPS (ttm) | -1.28 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $13.39 |
| Previous Close | $13.42 |
| Change ($) | -0.03 |
| Change (%) | -0.22% |
| Day's Open | 13.46 |
| Day's Range | 13.05 - 13.57 |
| Day's Volume | 647,338 |
| 52-Week Range | 7.98 - 25.64 |
Adverum Biosciences stock, a clinical stage gene therapy company focused on serious ocular and rare diseases, has rallied by a solid 18% over the last 5 trading days, after the company disclos...
Adverum Biotechnologies (ADVM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Investors need to pay close attention to Adverum Biotechnologies (ADVM) stock based on the movements in the options market lately.
-- 174,000-square-foot commercial GMP facility in Durham, NC for the manufacturing of ADVM-022, an intravitreal gene therapy in development for wet AMD and DME -- -- Multiple production suites...
REDWOOD CITY, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare dis...
-- Maintained efficacy and greatly reduced anti-VEGF treatment burden after a single IVT injection of ADVM-022 -- -- R obust preliminary aqueous a nti-VEGF protein expression observed at 18 m...
Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of 11.43% and -100.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead...
-- Dr. Carl Regillo to present OPTIC data a t the R etina S ubspecialty D ay on Friday, November 13, 2020 at 2:15 pm PT -- -- Company to host webcast with key opinion leaders on Saturday , No...
Investors need to pay close attention to Adverum Biotechnologies (ADVM) stock based on the movements in the options market lately.
Today, we take an in-depth look at Adverum Biotechnologies which has dropped by more than half from highs earlier this year.
REDWOOD CITY, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rar...
REDWOOD CITY, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare d...
Adverum (ADVM) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
REDWOOD CITY, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare di...
REDWOOD CITY, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare di...
Adverum Biotechnologies, Inc. (ADVM) CEO Laurent Fischer on Q2 2020 Results - Earnings Call Transcript
Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of -20.00% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for...
REDWOOD CITY, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare d...
REDWOOD CITY, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare...
-- INFINITY trial is currently enrolling patients with DME, the most common cause of vision loss in people with diabetic retinopathy -- REDWOOD CITY, Calif., July 13, 2020 (GLOBE NEWSWIRE)...
-- Patients in Cohort 4 received ADVM-022 high dose 6x1011 vg and prophylactic steroid eye drops -- -- Data from all four cohorts planned by the end of 2020 --
-- Plans underway to begin expansion of manufacturing capabilities -- REDWOOD CITY, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stag...
-- Laurent Fischer, M.D. joins as CEO -- -- Leone Patterson will continue to serve as president -- REDWOOD CITY, Calif., June 15, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (...
Adverum Biotechnologies, Inc. (ADVM) CEO Leone Patterson on Q1 2020 Results - Earnings Call Transcript
Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of -14.81% and -100.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead fo...
Is (ADVM) Outperforming Other Medical Stocks This Year?
AbbVie, Adverum Biotechnologies, and Heron Therapeutics could all be gearing up for a strong May. Here's why.
Is (ADVM) Outperforming Other Medical Stocks This Year?
The company's experimental gene therapy for a common cause of blindness showed promise in a clinical trial.
Adverum Biotechnologies said Tuesday the effect of its gene therapy on an eye disease lasted for more than a year in a Phase 1 test of six patients — prodding Adverum stock to rocket. The pos...
Adverum's lead gene therapy candidate continues to impress in its early-stage trial.
-- Robust efficacy and evidence of a dose response from single intravitreal injection (IVT) of ADVM-022 -- -- Long-term durability beyond 1 year from single IVT injection of ADVM-022 with ...
Does Adverum Biotechnologies (ADVM) have what it takes to be a top stock pick for momentum investors? Let's find out.
Adverum Biotechnologies (ADVM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
REDWOOD CITY, Calif., April 20, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare ...
Adverum (ADVM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well
Adverum Biotechnologies (ADVM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Adverum Biotechnologies, Inc. (ADVM) CEO Leone Patterson on Q4 2019 Results - Earnings Call Transcript
Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of 6.45% and -100.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead f...
Adverum (ADVM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Adverum Biotechnologies (ADVM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
REDWOOD CITY, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare d...
REDWOOD CITY, Calif., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare d...
Adverum Biotechnologies Inc (NASDAQ: ADVM) shares were trading higher Monday in reaction to a presentation of data from a Phase 1 study of its experimental gene therapy to treat wet age-relate...
Interim results from an early-stage study of its wet age-related macular degeneration treatment look promising.
-- Robust efficacy with evidence of a dose response -- -- 6/6 patients rescue-injection-free in cohort 1, with 3 patients at 52 weeks -- -- 4/6 patients rescue-injection-free in cohort 2 (l...
- New headquarters includes 80,000 square feet of office, laboratory, and manufacturing space to advance the development of Adverum’s novel gene therapies -
Adverum Biotechnologies: Keep On Your Watchlist In 2020
-- OPTIC phase 1 trial progressing with plans to complete patient dosing in cohort three, begin enrollment in cohort four in 1Q20 -- -- IND application planned for ADVM-022 in diabetic reti...
About ADVM
Adverum Biotechnologies, a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema. The company has collaborat... [Read more...]
| Industry Biotechnology | IPO Date Jul 31, 2014 |
| CEO Leone Patterson | Employees 114 |
| Stock Exchange NASDAQ | Ticker Symbol ADVM |
Financial Performance
In 2019, ADVM's revenue was $250,000, a decrease of -84.49% compared to the previous year's $1.61 million. Losses were -$64.49 million, -11.21% less than in 2018.
Analyst Forecasts
According to 11 analysts, the average rating for ADVM stock is "Buy." The 12-month stock price forecast is 25.22, which is an increase of 88.35% from the latest price.